研究单位：[1]Merck Sharp & Dohme LLC[2]AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0129),Orlando,Florida,United States,32804[3]Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0108),Marietta,Georgia,United States,30060[4]University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0124),Lexington,Kentucky,United States,40536[5]The West Clinic, PLLC dba West Cancer Center ( Site 0110),Germantown,Tennessee,United States,38138[6]James Lind Centro de Investigacion del Cancer ( Site 0506),Temuco,Araucania,Chile,4800827[7]FALP-UIDO ( Site 0500),Santiago,Region M. De Santiago,Chile,7500921[8]Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0503),Santiago,Region M. De Santiago,Chile,7501010[9]Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 0502),Santiago,Region M. De Santiago,Chile,7620002[10]Bradfordhill-Clinical Area ( Site 0501),Santiago,Region M. De Santiago,Chile,8420383[11]Second Affiliated hospital of Anhui Medical University-Oncology ( Site 3038),Hefei,Anhui,China,230000[12]Chongqing University Three Gorges Hospital ( Site 3036),Wanzhou,Chongqing,China,404000[13]Sun Yatsen University Cancer Center ( Site 3001),Guangzhou,Guangdong,China,510060[14]Southern Medical University Nanfang Hospital-Department of Oncology ( Site 3019),Guangzhou,Guangdong,China,510515[15]Cancer Hospital of Shantou University Medical College ( Site 3034),Shantou,Guangdong,China,515041[16]Fourth Hospital of Hebei Medical University ( Site 3015),Shijiazhuang,Hebei,China,050035[17]Sichuan Cancer hospital ( Site 3030),Chengdu,Sichuan,China,610213[18]Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Oncology ( Site 3006),Hangzhou,Zhejiang,China,310016[19]Taizhou Hospital of Zhejiang Province ( Site 3020),Linhai,Zhejiang,China,317000[20]Queen Mary Hospital ( Site 3100),Hksar,Hong Kong[21]Prince of Wales Hospital ( Site 3102),Shatin,Hong Kong[22]Hillel Yaffe Medical Center ( Site 1604),Hadera,Israel,3810101[23]Rambam Health Care Campus-Oncology Division ( Site 1600),Haifa,Israel,3109601[24]Hadassah Medical Center ( Site 1603),Jerusalem,Israel,9112001[25]Rabin Medical Center ( Site 1605),Petah Tikva,Israel,4941492[26]Sourasky Medical Center ( Site 1602),Tel Aviv,Israel,64239[27]National Cancer Center Hospital East ( Site 3300),Kashiwa,Chiba,Japan,277-8577[28]Kochi Medical School Hospital ( Site 3304),Nankoku,Kochi,Japan,783-8505[29]Saitama Prefectural Cancer Center ( Site 3302),Kitaadachi-gun,Saitama,Japan,362-0806[30]National Cancer Center Hospital ( Site 3301),Chuo,Tokyo,Japan,104-0045[31]The Cancer Institute Hospital of JFCR ( Site 3306),Koto,Tokyo,Japan,135-8550[32]National Hospital Organization Kyushu Cancer Center ( Site 3303),Fukuoka,Japan,811-1395[33]Seoul National University Bundang Hospital ( Site 3504),Seongnam,Kyonggi-do,Korea, Republic of,13620[34]Seoul National University Hospital-Oncology ( Site 3503),Seoul,Korea, Republic of,03080[35]Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3500),Seoul,Korea, Republic of,03722[36]Asan Medical Center-Department of Oncology ( Site 3501),Seoul,Korea, Republic of,05505[37]Samsung Medical Center-Division of Hematology/Oncology ( Site 3502),Seoul,Korea, Republic of,06351[38]The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 3505),Seoul,Korea, Republic of,06591[39]Sarawak General Hospital-Radiotherapy Unit ( Site 3401),Kuching,Sarawak,Malaysia,93586[40]National Cancer Institute-Radiotherapy and Oncology ( Site 3404),Putrajaya,Wilayah Persekutuan Putrajaya,Malaysia,62250[41]Hospital Universitario Marqués de Valdecilla ( Site 1901),Santander,Cantabria,Spain,39008[42]Ninewells Hospital and Medical School-Oncology Petty ( Site 2209),Dundee,Dundee City,United Kingdom,DD2 1SG[43]The Christie NHS Foundation Trust-Medical Oncology ( Site 2201),Manchester,United Kingdom,m20 4bx
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
